Molbio-Diagnostics-Limited

Molbio Diagnostics Limited (NEW IPO): GMP, Profit, Price & expert review

by

Molbio Diagnostics Limited is an Indian medical diagnostics company that develops and manufactures point-of-care molecular diagnostic technologies, including its flagship Truenat platform – a portable, battery-operated PCR system used to deliver rapid test results (within about an hour) for infectious diseases such as tuberculosis (TB), COVID-19, HIV, HPV, and hepatitis B & C. It operates multiple manufacturing facilities in India and serves both domestic and international markets.

Molbio Diagnostics Limited was incorporated in 2000 & currently Mr. Sriram Natarajan serves as the Executive Director & Chief Executive Officer (CEO) of the company.

It has exported its Truenat platform to over 85 countries with over ~10,000 installations globally and has empowered diagnostics for 40 + million individuals. It is the Truenat point-of-care molecular diagnosis platform – a portable, battery-operated PCR system that provides rapid testing for infectious and selected non-communicable diseases.

Molbio Diagnostics has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an IPO consisting Fresh Issue of ₹ 200 Crore and an Offer-for-Sale (OFS) of 12,556,000 Equity Shares.

Subscription date to apply for Molbio Diagnostics Limited is yet to be announced. Price band for the IPO is also pending to be declared.

Check DRHP
Check IPO Allotment
Visit Official Website
Issue Size:₹ 200 Cr + 12,556,000 Equity Shares
Fresh Issue:₹ 200 Cr
Offer for Sale:12,556,000 Equity Shares
Price Range:TBA
Lot Size:TBA
GMPPending

Molbio Diagnostics Limited important data points

Revenue, PAT, EBITDA

YearFiscal 2025
Networth₹ 952.94 Cr
Revenue:₹ 1020.41 Cr
EBITDA₹ 256.63 Cr
EBITDA Margin:~24.97%
PAT₹ 138.57 Cr
PAT Margin~13.48%
Face Value:₹ 1
ROE110.23%
ROCE45.54%
RoNW110.23%

IPO important dates

Open Date:TBA
Close Date:TBA
Anchor Investor BiddingTBA
Allotment Date:TBA
Refunds & Demat CreditTBA
Tentative Listing Date:TBA

Use of Proceeds

PurposeAmount
Technology & Infrastructure~ ₹ 99.36 Cr
Purchasing Plant & Machinery~ ₹ 73.49 Cr
Sales and Marketing~ ₹ 00 Cr
Loan Prepayment₹ 00 Cr
General Corporate Purpose₹ 00 Cr

Molbio Diagnostics Limited Financial Data

202320242025
Revenue (₹ Cr)₹ 332.46₹ 836.56₹ 1020.41
PAT (₹ Cr)₹ -3.44₹ 83.54₹ 138.57
Asset (₹ Cr)₹ 1034.21₹ 1221.05₹ 1461.55
Net Worth (₹ Cr)₹ 706.03₹ 807.93₹ 952.94

Molbio Diagnostics Limited IPO Grey Market Premium

DateIPO PriceIPO GMPProfit per lot
22-Apr₹ –₹ –₹ –
21-Apr₹ –₹ –₹ –
20-Apr₹ –₹ –₹ –
19-Apr₹ –₹ –₹ –
18-Apr₹ –₹ –₹ –
Molbio Diagnostics Limited

Molbio Diagnostics Limited IPO Pros & Cons

Strengths:

  • Proprietary Truenat technology with global WHO endorsement for TB and multi-disease testing.
  • Strong revenue growth with a profitable track record ahead of IPO filing.
  • Large recurring revenue potential from consumable test kits sales.
  • Global footprint with installations in 80 + countries.
  • Backbone of frontline public health programs in India and abroad.

Risks:

  • Highly dependent on government/public healthcare purchases for revenue
  • Top customers concentration risk (major portion of sales comes from top 10 clients).
  • Limited diversification beyond molecular diagnostics currently.
  • Inventory and working capital intensity risks due to perishable test kits.
  • Vulnerable to competitive molecular diagnostic technologies and pricing pressure.

Molbio Diagnostics Limited Promoters – Pre offer equity (Approx)

Promoters%Shares
Exxora Trading LLP~ 41.23 %
Dr. Chandrasekhar Bhaskaran Nair~ 5.42 %
––
––
––
––

Molbio Diagnostics Limited Promoters – Pre offer equity (Approx)

Application TypeLot SizeNo. of LotNo. of SharesInvestment Amount
Retail (Min)–1–₹ –
Retail (Max)–13–₹ –
HNI (Min)–14–₹ –
HNI (Max)–66–₹ –
Big HNI (Min)–67–₹ –

Lead Managers / Registrars of Molbio Diagnostics Limited

Lead / Book Running Lead ManagersKotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited
Registrar (RTA)KFin Technologies Limited

FAQ’S of Intellius Recode Limited

  • It is an Indian molecular diagnostics firm that makes Truenat point-of-care PCR devices and test kits for rapid detection of infectious diseases like TB, COVID-19, HIV and more.

  • Molbio Technologies is raising funds via IPO to raise capital for R&D facilities, a Centre of Excellence, and machinery upgrades for its manufacturing units, plus general corporate use.

  • The issue size of the IPO comprises of ₹ 200 Cr as Fresh Issue + OFS ~1.26 Cr equity shares. It will be listed on BSE and NSE platform.

  • Key risks include high dependence on public healthcare/government contracts, customer concentration, and reliance on TB test revenues.

  • Upsides include strong global adoption of Truenat tech, recurring test kit sales, solid revenue growth and WHO recognition for key tests.

  • Investors can apply for the IPO through ASBA via net banking or using UPI through registered stock brokers once the IPO opens for subscription.

For more amazing blogs click here (IPO Corner).

Leave a comment